Literature DB >> 2614458

Norpethidine induced myoclonus in a patient with renal failure.

D C Reutens, E G Stewart-Wynne.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2614458      PMCID： PMC1031622          DOI： 10.1136/jnnp.52.12.1450

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  6 in total

1.  Meperidine-associated myoclonus and seizures in long-term hemodialysis patients.

Authors:  M S Hochman
Journal:  Ann Neurol       Date:  1983-11       Impact factor: 10.422

2.  Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure of cancer.

Authors:  H H Szeto; C E Inturrisi; R Houde; S Saal; J Cheigh; M M Reidenberg
Journal:  Ann Intern Med       Date:  1977-06       Impact factor: 25.391

3.  Antagonism of the convulsant effects of heroin, d-propoxyphene, meperidine, normeperidine and thebaine by naloxone in mice.

Authors:  P E Gilbert; W R Martin
Journal:  J Pharmacol Exp Ther       Date:  1975-03       Impact factor: 4.030

4.  Uraemic myoclonus: an example of reticular reflex myoclonus?

Authors:  D Chadwick; A T French
Journal:  J Neurol Neurosurg Psychiatry       Date:  1979-01       Impact factor: 10.154

Review 5.  Mechanism of action of clonazepam in myoclonus in relation to effects on GABA and 5-HT.

Authors:  P Jenner; J A Pratt; C D Marsden
Journal:  Adv Neurol       Date:  1986

6.  Central nervous system excitatory effects of meperidine in cancer patients.

Authors:  R F Kaiko; K M Foley; P Y Grabinski; G Heidrich; A G Rogers; C E Inturrisi; M M Reidenberg
Journal:  Ann Neurol       Date:  1983-02       Impact factor: 10.422
  6 in total
  2 in total

Review 1.  Drug-induced movement disorders.

Authors:  F J Jiménez-Jiménez; P J García-Ruiz; J A Molina
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

Review 2.  Drug-induced myoclonus: frequency, mechanisms and management.

Authors:  Félix Javier Jiménez-Jiménez; Inmaculada Puertas; María de Toledo-Heras
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.